- Home
- BMRC vs ERAS Comparison
BMRC vs ERAS Comparison
Compare BMRC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- ERAS
- Stock Information
- Founded
- BMRC 1989
- ERAS 2018
- Country
- BMRC United States
- ERAS United States
- Employees
- BMRC N/A
- ERAS N/A
- Industry
- BMRC Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- ERAS Health Care
- Exchange
- BMRC Nasdaq
- ERAS Nasdaq
- Market Cap
- BMRC 394.5M
- ERAS 432.6M
- IPO Year
- BMRC N/A
- ERAS 2021
- Fundamental
- Price
- BMRC $19.81
- ERAS $1.12
- Analyst Decision
- BMRC Strong Buy
- ERAS Strong Buy
- Analyst Count
- BMRC 3
- ERAS 6
- Target Price
- BMRC $28.00
- ERAS $4.83
- AVG Volume (30 Days)
- BMRC 63.2K
- ERAS 1.8M
- Earning Date
- BMRC 04-28-2025
- ERAS 05-07-2025
- Dividend Yield
- BMRC 4.89%
- ERAS N/A
- EPS Growth
- BMRC N/A
- ERAS N/A
- EPS
- BMRC N/A
- ERAS N/A
- Revenue
- BMRC $67,983,000.00
- ERAS N/A
- Revenue This Year
- BMRC $63.26
- ERAS N/A
- Revenue Next Year
- BMRC $9.68
- ERAS N/A
- P/E Ratio
- BMRC N/A
- ERAS N/A
- Revenue Growth
- BMRC N/A
- ERAS N/A
- 52 Week Low
- BMRC $14.11
- ERAS $1.04
- 52 Week High
- BMRC $27.11
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- BMRC 22.12
- ERAS 32.58
- Support Level
- BMRC $21.51
- ERAS $1.04
- Resistance Level
- BMRC $22.50
- ERAS $1.61
- Average True Range (ATR)
- BMRC 0.93
- ERAS 0.12
- MACD
- BMRC -0.22
- ERAS -0.02
- Stochastic Oscillator
- BMRC 4.70
- ERAS 24.56
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.